Design of iron chelators with therapeutic application

Free radicals in biology and medicine

Gutteridge, J. M. C. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90478-o · Cited by 17,178

Critical Stability Constants

Martell, A. E., & Smith, R. M. (1982) · Springer eBooks · doi:10.1007/978-1-4615-6761-5 · Cited by 6,025

Free Radicals in Biology and Medicine

Land, E. J. (1990) · International Journal of Radiation Biology · doi:10.1080/09553009014552071 · Cited by 4,871

Disorders of Iron Metabolism

Andrews, N. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412607 · Cited by 2,130

Hematology: Basic Principles and Practice

(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,862

Undetectable Intracellular Free Copper: The Requirement of a Copper Chaperone for Superoxide Dismutase

Rae, T., Schmidt, P. J., Pufahl, R. A., Culotta, V., & O’Halloran, T. V. (1999) · Science · doi:10.1126/science.284.5415.805 · Cited by 1,640

Principles of bioinorganic chemistry

(1995) · Choice Reviews Online · doi:10.5860/choice.32-4515 · Cited by 1,538

Principles of bioinorganic chemistry

Chayen, J. (1995) · Cell Biochemistry and Function · doi:10.1002/cbf.290130214 · Cited by 1,060

Increased nigral iron content in postmortem parkinsonian brain

Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963

Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability

Levin, V. A. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00180a022 · Cited by 817

The Thalassæmia Syndromes.

(1973) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1973.tb111034.x · Cited by 808

Combinatorial Materials Science and Catalysis

Jandeleit, B., Schaefer, D. J., Powers, T. S., Turner, H. W., & Weinberg, W. H. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990903)38:17 · Cited by 629

Transition Metals in Control of Gene Expression

O’Halloran, T. V. (1993) · Science · doi:10.1126/science.8342038 · Cited by 626

The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism

Keberle, H. (1964) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb54077.x · Cited by 617

Physicochemical Principles of Pharmacy

Florence, A. T., & Attwood, D. (1981) · doi:10.1007/978-1-349-19480-3 · Cited by 605

Inorganic Biochemistry of Iron Metabolism: From Molecular Mechanisms to Clinical Consequences

Crichton, R. (2001) · doi:10.1002/0470845791 · Cited by 453

The Thalassaemia Syndromes

Stamatoyannopoulos, G. (1982) · JAMA · doi:10.1001/jama.1982.03330130096049 · Cited by 441

Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions

Olivieri, N. F., Buncic, J. R., Chew, E., Gallant, T., Harrison, R. V., Keenan, N. K., Logan, W. J., Mitchell, D., Ricci, G., Skarf, B., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604033141402 · Cited by 425

IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA

Pippard, M. J., Warner, G. T., Callender, S. T., & Weatherall, D. J. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92175-5 · Cited by 419

Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major

Olivieri, N. F., Brittenham, G. M., McLaren, C. E., Templeton, D. M., Cameron, R., MCCLELLAND, R. A., Burt, A. D., & Fleming, K. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390701 · Cited by 418

Lipid solubility and drug penetration of the blood brain barrier

Oldendorf, W. H. (1974) · Experimental Biology and Medicine · doi:10.3181/00379727-147-38444 · Cited by 373

Complexation of iron by siderophores a review of their solution and structural chemistry and biological function

Raymond, K. N., Müller, G., & Matzanke, B. F. (1984) · Topics in Current Chemistry · doi:10.1007/3-540-13099-3_2 · Cited by 357

Intestinal permeability: functional assessment and significance

Travis, S. P. L., & Menzies, I. S. (1992) · Clinical Science · doi:10.1042/cs0820471 · Cited by 343

Siderophore mediated absorption of iron

Hider, R. C. (2007) · Structure and Bonding · doi:10.1007/bfb0111310 · Cited by 261

Iron and infection: molecular, physiological and clinical aspects.

Bullen, J. J., & Griffiths, E. (1999) · Cited by 244

Lactulose 51Cr-labelled ethylenediaminetetra-acetate, l -rhamnose and polyethyleneglycol 500 as probe markers for assessment in vivo of human intestinal permeability

Maxton, D. G., Bjarnason, I., Reynolds, A., Catt, S. D., Peters, T. J., & Menzies, I. S. (1986) · Clinical Science · doi:10.1042/cs0710071 · Cited by 204

Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients

Hoffbrand, A. V., Al‐Refaie, F. N., Davis, B. A., Siritanakatkul, N., Jackson, B. F. A., Cochrane, J. P. S., Prescott, E., & Wonke, B. (1998) · Blood · doi:10.1182/blood.v91.1.295 · Cited by 203

Activation of the CPP32 Apoptotic Protease by Distinct Signaling Pathways with Differential Sensitivity to Bcl-xL

Erhardt, P., & Cooper, G. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17601 · Cited by 190

Citrate binding of Al3+ and Fe3+

Martin, R. B. (1986) · Journal of Inorganic Biochemistry · doi:10.1016/0162-0134(86)80081-2 · Cited by 189

Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron‐Loaded Subjects

Summers, M. R., Jacobs, A., Tudway, D. C., Perera, P., & Ricketts, C. (1979) · British Journal of Haematology · doi:10.1111/j.1365-2141.1979.tb01167.x · Cited by 179

The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase

Cooper, C. E., Lynagh, G. R., Hoyes, K. P., Hider, R. C., Cammack, R., & Porter, J. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20291 · Cited by 176

Facilitation of Fe(II) antoxidation by Fe(III) complexing agents

Harris, D. C., & Aisen, P. (1973) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(73)90019-6 · Cited by 172

Iron Chelators for Thalassaemia

Hershko, C., Konijn, A. M., & Link, G. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00726.x · Cited by 159

The Development of Iron Chelators for Clinical Use

Brittenham, G. M., & Bergeron, R. J. (1993) · Medical Entomology and Zoology · Cited by 158

New Multidentate Ligands. VI. Chelating Tendencies of N,N′-Di(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic Acid

Eplattenier, F. L., Murase, I., & Martell, A. E. (1967) · Journal of the American Chemical Society · doi:10.1021/ja00980a019 · Cited by 158

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture

Hershko, C., Konijn, A. M., Nick, H. P., Breuer, W. V., Cabantchik, Z. I., & Link, G. (2001) · Blood · doi:10.1182/blood.v97.4.1115 · Cited by 151

Deferiprone

Balfour, J. A. B., & Foster, R. H. (1999) · Drugs · doi:10.2165/00003495-199958030-00021 · Cited by 148

Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

Porter, J. B., Jaswon, M. S., Huehns, E. R., East, C. A., & Hazell, J. W. P. (1989) · British Journal of Haematology · doi:10.1111/j.1365-2141.1989.tb07761.x · Cited by 148

Structure, properties, and transport mechanism of iron(III) complex of mugineic acid, a possible phytosiderophore

Sugiura, Y., Tanaka, H., Mino, Y., Ishida, T., Ota, N., Inoue, M., Nomoto, K., Yoshioka, H., & TAKEMOTO, T. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00413a043 · Cited by 148

Isolation and characterization of staphyloferrin A, a compound with siderophore activity from Staphylococcus hyicus DSM 20459

Meiwes, J., Fiedler, H.-P., Haag, H., Zähner, H., Konetschny-Rapp, S., & Jung, G. (1990) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1990.tb13863.x · Cited by 140

Hydrolytic polymerization of ferric citrate. II. Influence of excess citrate

Spiro, T. G., Bates, G. W., & Saltman, P. (1967) · Journal of the American Chemical Society · doi:10.1021/ja00998a009 · Cited by 140

Hydroxylated Phytosiderophore Species Possess an Enhanced Chelate Stability and Affinity for Iron(III)

von Wirén, N., Khodr, H., & Hider, R. C. (2000) · PLANT PHYSIOLOGY · doi:10.1104/pp.124.3.1149 · Cited by 138

Growth Failure and Bony Changes Induced by Deferoxamine

Olivieri, N. F., Koren, G., Harris, J., Khattak, S., Freedman, M. H., Templeton, D. M., Bailey, J. D., & Reilly, B. J. (1992) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199221000-00007 · Cited by 129

Structural studies of transition metal complexes of triionized and tetraionized citrate. Models for the coordination of the citrate ion to transition metal ions in solution and at the active site of aconitase

Strouse, J., Layten, S. W., & Strouse, C. E. (1977) · Journal of the American Chemical Society · doi:10.1021/ja00444a041 · Cited by 129

Ferric ion sequestering agents. 15. Synthesis, solution chemistry, and electrochemistry of a new cationic analog of enterobactin

RODGERS, S. J., Lee, C. W., Ng, C. Y., & Raymond, K. N. (1987) · Inorganic Chemistry · doi:10.1021/ic00257a030 · Cited by 127

Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease

Richardson, D. R., & Ponka, P. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90180-9 · Cited by 126

Rhizoferrin: A complexone type siderophore of the mocorales and entomophthorales (Zygomycetes)

Thieken, A., & Winkelmann, G. ⁄. N. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05285.x · Cited by 126

2 Clinically Useful Chelators of Tripositive Elements

Hider, R. C., & Hall, A. D. (1991) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70363-1 · Cited by 119

Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, iron(III)-chelating properties and biological activity

Streater, M., Taylor, P. D., Hider, R. C., & Porter, J. B. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00168a033 · Cited by 115

Pulmonary Syndrome in Patients With Thalassemia Major Receiving Intravenous Deferoxamine Infusions

Freedman, M. H. (1990) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1990.02150290059028 · Cited by 114

Iron and citric acid: A fuzzy chemistry of ubiquitous biological relevance

Pierre, J. L., & Gautier‐Luneau, I. (2000) · BioMetals · doi:10.1023/a:1009225701332 · Cited by 113

Rational reduction of the conformational space of a siderophore analog through nonbonded interactions: the role of entropy in enterobactin

Stack, T. D. P., Hou, Z., & Raymond, K. N. (1993) · Journal of the American Chemical Society · doi:10.1021/ja00067a094 · Cited by 111

Inorganic biochemistry of iron metabolism

Eastham, B. (1992) · Biochemical Education · doi:10.1016/0307-4412(92)90222-8 · Cited by 109

Synthesis, Physicochemical Properties, and Evaluation ofN-Substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones

Rai, B. L., Dekhordi, L. S., Khodr, H., Jin, Y., Liu, Z. D., & Hider, R. C. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9707784 · Cited by 108

Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands

White, D. L., Durbin, P. W., Jeung, N., & Raymond, K. N. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00396a005 · Cited by 102

Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice [see comments]

Porter, J. B., Morgan, J., Hoyes, K. P., Burke, L., Huehns, E. R., & Hider, R. C. (1990) · Blood · doi:10.1182/blood.v76.11.2389.2389 · Cited by 100

A Risk-Benefit Assessment of Iron-Chelation Therapy

Porter, J. B. (1997) · Drug Safety · doi:10.2165/00002018-199717060-00006 · Cited by 95

Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines.

Hoyes, K. P., Hider, R. C., & Porter, J. B. (1992) · PubMed · Cited by 95

Model compounds for microbial iron-transport compounds. Part 1. Solution chemistry and Mössbauer study of iron( II ) and iron( III ) complexes from phenolic and catecholic systems

Hider, R. C., Mohd-Nor, A. R., Silver, J., MORRISON, I. E. G., & Rees, L. V. C. (1981) · Journal of the Chemical Society Dalton Transactions · doi:10.1039/dt9810000609 · Cited by 93

Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia [see comments]

Gordeuk, V., Thuma, P., Brittenham, G., Zulu, S., Simwanza, G., Mhangu, A., Flesch, G., & Parry, D. (1992) · Blood · doi:10.1182/blood.v79.2.308.308 · Cited by 90

Synthesis, Physicochemical Characterization, and Biological Evaluation of 2-(1‘-Hydroxyalkyl)-3-hydroxypyridin-4-ones: Novel Iron Chelators with Enhanced pFe3+ Values

Liu, Z. D., Khodr, H., Liu, D. Y., Lu, S. L., & Hider, R. C. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm991080o · Cited by 89

Hemochromatosis : genetics, pathophysiology, diagnosis, and treatment

Barton, J. C., & Edwards, C. Q. (2000) · Cambridge University Press eBooks · Cited by 86

Jejunal permeability in humans invivo and rats insitu: investigation of molecular size selectivity and solvent drag

FAGERHOLM, NILSSON, Knutson, & LENNERNÄS (1999) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.1999.00510.x · Cited by 85

Evaluation of desferrithiocin and its synthetic analogs as orally effective iron chelators

Bergeron, R. J., Wiegand, J., Dionis, J. B., Egli-Karmakka, M., Frei, J., Huxley‐Tencer, A., & PETER, H. H. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00111a023 · Cited by 84

Light Dose Fractionation to Enhance Photodynamic Therapy Using 5-Aminolevulinic Acid in the Normal Rat Colon

Curnow, A., Mcllroy, B. W., Postle‐Hacon, M. J., MacRobert, A. J., & Bown, S. G. (1999) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1999.tb05308.x · Cited by 84

Specific Sequestering Agents for the Actinides. 28. Synthesis and Initial Evaluation of Multidentate 4-Carbamoyl-3-hydroxy-1-methyl-2(1H)-pyridinone Ligands for in Vivo Plutonium(IV) Chelation

Xu, J., Kullgren, B., Durbin, P. W., & Raymond, K. N. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00014a013 · Cited by 83

Chelation and Mobilization of Cellular Iron by Different Classes of Chelators

Zanninelli, G., Glickstein, H., Breuer, W., Milgram, P., Brissot, P., Hider, R. C., Konijn, A. M., Libman, J., Shanzer, A., & Cabantchik, Z. I. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.842 · Cited by 83

Development of iron-chelating agents for clinical use [editorial; comment]

Brittenham, G. (1992) · Blood · doi:10.1182/blood.v80.3.569.bloodjournal803569 · Cited by 77

Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.

Hershko, C., AVRAMOVICI‐GRISARU, S., Link, G., GELFAND, L. S., & Sarel, S. (1981) · PubMed · Cited by 76

Biliary Iron Excretion in Rats following Pyridoxal Isonicotinoyl Hydrazone

Cikrt, M., Poňka, P., Nečas, E., & Neuwirt, J. (1980) · British Journal of Haematology · doi:10.1111/j.1365-2141.1980.tb07147.x · Cited by 76

A comparison of the iron-clearing properties of 1,2-dimethyl-3- hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine

Bergeron, R. J., Streiff, R., Wiegand, J. S., Luchetta, G. R., Creary, E., & Peter, H. (1992) · Blood · doi:10.1182/blood.v79.7.1882.1882 · Cited by 75

Iron chelation using subcutaneous infusions of diethylene triamine penta‐acetic acid (DTPA)

Pippard, M. J., Jackson, M. J., Hoffman, K., Petrou, M., & Modell, C. B. (1986) · Scandinavian Journal of Haematology · doi:10.1111/j.1600-0609.1986.tb02282.x · Cited by 73

High-Yield Synthesis of the Enterobactin Trilactone and Evaluation of Derivative Siderophore Analogs1

Meyer, M., Telford, J. R., Cohen, S. M., White, D. J., Xu, J., & Raymond, K. N. (1997) · Journal of the American Chemical Society · doi:10.1021/ja970718n · Cited by 72

Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.

Singh, S., Epemolu, R. O., Dobbin, P. S., Tilbrook, G. S., Ellis, B. L., Damani, L. A., & Hider, R. C. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08575-7 · Cited by 72

The Environment of the Lipoxygenase Iron Binding Site Explored with Novel Hydroxypyridinone Iron Chelators

Abeysinghe, R. D., Roberts, P. J., Cooper, C. E., MacLean, K. H., Hider, R. C., & Porter, J. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.7965 · Cited by 70

Design, Synthesis, and Evaluation of Novel 2-Substituted 3-Hydroxypyridin-4-ones: Structure−Activity Investigation of Metalloenzyme Inhibition by Iron Chelators

Liu, Z. D., Kayyali, R., Hider, R. C., Porter, J. B., & Theobald, A. E. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010817i · Cited by 70

The development of new iron-chelating drugs.

Grady, R. W., Graziano, J., Akers, H. A., & Cerami, A. (1976) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30436-2 · Cited by 70

Effect of Desferrioxamine and D.T.P.A. in Iron Overload

Bannerman, R. M., Callender, S. T., & Williams, D. L. (1962) · BMJ · doi:10.1136/bmj.2.5319.1573 · Cited by 69

Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents

Curnow, A., Mcllroy, B., Postle-Hacon, M., Porter, J., MacRobert, A., & Bown, S. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.671 · Cited by 68

Investigation into the correlation between the structure of hydroxypyridinones and blood–brain barrier permeability

Habgood, M. D., Liu, Z. D., Saghaei, L., Khodr, H., Abbott, J., & Hider, R. C. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00031-3 · Cited by 67

HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy

Bergeron, R. J., Wiegand, J., & Brittenham, G. M. (1998) · Blood · doi:10.1182/blood.v91.4.1446 · Cited by 66

Intensive Iron-Chelation Therapy with Desferrioxamine in Iron-Loading Anaemias

Pippard, M. J., Callender, S. T., & Weatherall, D. J. (1978) · Clinical Science · doi:10.1042/cs0540099 · Cited by 66

Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration.

Brittenham, G. M. (1990) · PubMed · Cited by 61

An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.

Johnson, D. K., Pippard, M. J., Murphy, T. B., & Rose, N. J. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33072-7 · Cited by 60

Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment

Felitti, V. J. (2000) · JAMA · doi:10.1001/jama.284.12.1581 · Cited by 59

New Insight into the Source of Biomolecular Homochirality: An Extraterrestrial Origin for Molecules of Life?

Podlech, J. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990215)38:4 · Cited by 59

The antimalarial effect of iron chelators: Studies in animal models and in humans with mild falciparum malaria

Hershko, C., Gordeuk, V. R., Brittenham, G. M., Thuma, P. E., Theanacho, E. N., Spira, D. T., Hider, R. C., & Peto, T. E. A. (1992) · Journal of Inorganic Biochemistry · doi:10.1016/0162-0134(92)84072-u · Cited by 57

Crystal structure of the tris 1,2-dimethyl-3-hydroxy-4-pyridinone (DMHP) complex with the Fe(III) ion

Clarke, E. T., Martell, A. E., & Reibenspies, J. H. (1992) · Inorganica Chimica Acta · doi:10.1016/s0020-1693(00)86121-6 · Cited by 57

New Considerations in the Treatment of Sickle Cell Disease

Reed, W., & Vichinsky, E. P. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.461 · Cited by 56

Physicochemical Principles of Pharmacy

Leslie, J. (1989) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/46.8.1678 · Cited by 55

Esters and lactones of phenolic amino carboxylic acids. Prodrugs for iron chelation

Pitt, C. G., Bao, Y. T., Thompson, J. B., Wani, M. C., Rosenkrantz, H., & Metterville, J. J. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00157a020 · Cited by 54

Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values

Liu, Z. D., Piyamongkol, S., Liu, D. Y., Khodr, H., Lu, S. L., & Hider, R. C. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00273-x · Cited by 53

Orally active hydroxamic acid inhibitors of leukotriene biosynthesis

Summers, J. B., Gunn, B. P., Martin, J. G., Mazdiyasni, H., Stewart, A. O., Young, P. R., Goetze, A. M., Bouska, J. B., & Dyer, R. D. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00396a002 · Cited by 51

Contrasting interspecies efficacy and toxicology of 1, 2 ‐diethy 1–3 ‐hydroxypyridin‐4‐one, CP9 4, relates to differing metabolism of the iron chelating site

Porter, J. B., Abeysinghe, R. D., Hoyes, K. P., Barra, C., Huehns, E. R., Brooks, P., Blackwell, M. P., Araneta, M. D. F., Brittenham, G., Singh, S. R. K., et al. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb08660.x · Cited by 50

Iron-Chelation Therapy with Oral Deferiprone — Toxicity or Lack of Efficacy?

Kowdley, K. V., & Kaplan, M. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390709 · Cited by 50

Metal complex formation of a new siderophore desferrithiocin and of three related ligands

Anderegg, G., & Raber, M. L. (1990) · Journal of the Chemical Society Chemical Communications · doi:10.1039/c39900001194 · Cited by 48

Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.

Hershko, C., Grady, R. W., & Cerami, A. (1978) · PubMed · Cited by 45

Coordination chemistry of microbial iron transport. 42. Structural and spectroscopic characterization of diastereomeric chromium(III) and cobalt(III) complexes of desferrithiocin

Hahn, F. E., McMurry, T. J., Hugi, A. D., & Raymond, K. N. (1990) · Journal of the American Chemical Society · doi:10.1021/ja00161a032 · Cited by 43

Therapeutic iron chelators and their potential side-effects

Singh, S., Khodr, H., Taylor, M. I., & Hider, R. C. (1995) · Biochemical Society Symposia · doi:10.1042/bss0610127 · Cited by 42

Potential protection from toxicity by oral iron chelators

Hider, R. C. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03606-7 · Cited by 41

Iron Chelation with Oral Deferiprone in Patients with Thalassemia

Tricta, F., & Spino, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392313 · Cited by 38

Results from a Phase I Clinical Trial of HBED

Grady, R. W., Hilgartner, M. W., Giardina, P. J., & Salbe, A. D. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2554-7_37 · Cited by 36

An Orally Active Iron Chelator

Nathan, D. G. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321411 · Cited by 36

Lessons from Preclinical and Clinical Studies with 1,2-Diethyl-3-Hydroxypyridin-4-One, CP94 and Related Compounds

Porter, J. B., Singh, S., Hoyes, K. P., Epemolu, O., Abeysinghe, R. D., & Hider, R. C. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2554-7_38 · Cited by 36

Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload.

Winston, A., Varaprasad, D. V. P. R., Metterville, J. J., & Rosenkrantz, H. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20911-9 · Cited by 35

Conformationally Rigid Tricyclic Tripods: Synthesis and Application to Preparation of Enterobactin Analogs

Tse, B., & Kishi, Y. (1994) · The Journal of Organic Chemistry · doi:10.1021/jo00104a043 · Cited by 35

Synthesis, physico-chemical and iron(III)-chelating properties of novel hexadentate 3-hydroxy-2(1H)pyridinone ligands

Rai, B. L., Khodr, H., & Hider, R. C. (1999) · Tetrahedron · doi:10.1016/s0040-4020(98)01091-6 · Cited by 35

Partition coefficients of the iron(III) complexes of pyridoxal isonicotinoyl hydrazone and its analogs and the correlation to iron chelation efficacy

Edward, J. T., Ponka, P., & Richardson, D. R. (1995) · BioMetals · doi:10.1007/bf00143378 · Cited by 32

Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic

Baker, E., Wong, A., Peter, H., & Jacobs, A. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08251.x · Cited by 30

Synthesis of N,N′-di(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid (HBED) and derivatives

Martell, A. E., Motekaitis, R. J., Clarke, E. T., & Harrison, J. J. (1986) · Canadian Journal of Chemistry · doi:10.1139/v86-070 · Cited by 28

Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: design of orally active chelators with clinical potential

Rai, B. L., Liu, Z. D., Liu, D. Y., Lu, S. L., & Hider, R. C. (1999) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(99)80097-x · Cited by 28

Improving the Oral Bioavailability of the Iron Chelator HBED by Breaking the Symmetry of the Intramolecular H-Bond Network

Faller, B., Spanka, C., Sergejew, T., & Tschinke, V. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990261n · Cited by 27

The Treatment of Malaria with Iron Chelators

Hider, R. C., & Liu, Z. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06162.x · Cited by 26

Absorption of Polyethylene Glycol Oligomers (330–1122 Da) Is Greater in the Jejunum than in the Ileum of Rats

Kim, M. (1996) · Journal of Nutrition · doi:10.1093/jn/126.9.2172 · Cited by 25

The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe3+ values

Hider, R. C., Liu, Z. D., & Piyamongkol, S. (2000) · Transfusion Science · doi:10.1016/s0955-3886(00)00090-4 · Cited by 25

The Synthesis, Crystal and Molecular Structure, and Oxidation State of Iron Complex from Pyridoxal Isonicotinoyl Hydrazone and Ferrous Sulphate

Avramovici‐Grisaru, S., Sarel, S., Cohen, S., & Bauminger, R. (1985) · Israel Journal of Chemistry · doi:10.1002/ijch.198500045 · Cited by 24

Synthesis, Physicochemical Properties and Biological Evaluation of Aromatic Ester Prodrugs of 1-(2‘-Hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): Orally Active Iron Chelators with Clinical Potential

Liu, Z. D., Liu, D. Y., Lu, S. L., & Hider, R. C. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772655 · Cited by 23

The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe3+ values

Liu, Z. D., Piyamongkol, S., & Hider, R. C. (2000) · Transfusion Science · doi:10.1016/s0955-3886(00)00106-5 · Cited by 22

Structure–activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase

Liu, Z. D., Lockwood, M., Rose, S., Theobald, A. E., & Hider, R. C. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00551-7 · Cited by 22

Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats

Zanninelli, G., Choudury, R., Loréal, O., Guyader, D., Lescoat, G., Arnaud, J., Verna, R., Cosson, B., Singh, S., Hider, R. C., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80299-1 · Cited by 20

In vivo iron mobilisation evaluation of hydroxypyridinones in 59Fe-ferritin-loaded rat model

Liu, Z. D., Lu, S. L., & Hider, R. C. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00319-0 · Cited by 20

DTPA in the management of iron overload in thalassaemia

Jackson, M. J., Brenton, D. P., & Modell, B. (1983) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01810345 · Cited by 20

Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators.

Yokel, R. A., Fredenburg, A. M., Meurer, K. A., & Skinner, T. L. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06763-7 · Cited by 20

Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.

Eh, L., Ea, C., Wright, B. J., & Ye, R. (1983) · PubMed · Cited by 19

Metabolism and pharmacokinetics of 1-(2′-hydroxyethyl)- and 1-(3′-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat

Singh, S., Choudhury, R., Epemolu, R. O., & Hider, R. C. (1996) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190276 · Cited by 17

Competition between iron(III)-selective chelators and zinc-finger domains for zinc(II)

Hider, R. C., Bittel, D., & Andrews, G. K. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00014-3 · Cited by 17

In Vitro and In Situ Permeability of a 'Second Generation' Hydroxypyridinone Oral Iron Chelator: Correlation with Physico-Chemical Properties and Oral Activity

Lowther, N., Fox, R., Faller, B., Nick, H., Jin, Y., Sergejew, T., Hirschberg, Y., Oberle, R. L., & Donnelly, H. (1999) · Pharmaceutical Research · doi:10.1023/a:1018886005136 · Cited by 15

Synthesis and physicochemical assessment of novel 2-substituted 3-hydroxypyridin-4-ones, novel iron chelators

Moridani, M. Y., Tilbrook, G. S., Khodr, H., & Hider, R. C. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778592 · Cited by 15

Caco-2 Cell Permeability of a New (Hydroxybenzyl)ethylenediamine Oral Iron Chelator: Correlation with Physicochemical Properties and Oral Activity

Lowther, N., Tomlinson, B., Fox, R., Faller, B., Sergejew, T., & Donnelly, H. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980191s · Cited by 14

Biliary and Urinary Metabolic Profiles of 1,2-Diethyl-3-hydroxypyridin-4-one (CP94) in the Rat

Lu, S. L., Gosriwatana, I., Liu, D. Y., Liu, Z. D., Mallet, A. I., & Hider, R. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15157-4 · Cited by 13

Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat.

Choudhury, R., Epemolu, R. O., Rai, B. L., Hider, R. C., & Singh, S. (1997) · PubMed · Cited by 12

Hydrolytic and Metabolic Characteristics of the Esters of1-(3'-Hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41), Potentially Useful Iron Chelators

Liu, D. Y., Liu, Z. D., Lu, S. L., & Hider, R. C. (2000) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2000.d01-40.x · Cited by 10

Application of Metal Coordination Chemistry To Explore and Manipulate Cell Biology

Haas, K. L., & Franz, K. J. (2009) · Chemical Reviews · doi:10.1021/cr900134a · Cited by 1,003

New metal complexes as potential therapeutics

Zhang, C. X., & Lippard, S. J. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00081-4 · Cited by 947

Iron(iii) selective molecular and supramolecular fluorescent probes

Sahoo, S. K., Sharma, D., Bera, R. K., Crisponi, G., & Callan, J. F. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35152h · Cited by 775

Bioinorganic Photochemistry: Frontiers and Mechanisms

Szacilowski, K. T., Macyk, W., Drzewiecka‐Matuszek, A., Brindell, M., & Stochel, G. (2005) · Chemical Reviews · doi:10.1021/cr030707e · Cited by 731

The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721

Design of clinically useful iron(III)‐selective chelators

Liu, Z. D., & Hider, R. C. (2002) · Medicinal Research Reviews · doi:10.1002/med.1027 · Cited by 266

Iron Chelator Chemistry

Liu, Z. D., Liu, D. Y., & Hider, R. C. (2002) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0593-8_8 · Cited by 15

The Design of Orally Active Iron Chelators

HIDER, R. C., & ZHOU, T. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.017 · Cited by 64

Iron Chelator Design

Hider, R. C., Epemolu, O., Singh, S., & Porter, J. B. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2554-7_36 · Cited by 19

Coordination Chemistry of Novel Drug Candidates for the Treatment of Iron Overload

Norin, A. (2007) · KTH Publication Database DiVA (KTH Royal Institute of Technology)